

September 25 - 26 2009, Juan-les-Pins - France







ASBL International Non-Profit Association under Belgian law IVZW



Guidelines for treatment of zygomycosis by ECIL 3

A. Skiada, A. Groll, R. Herbrecht,
F. Lanternier, O. Lortholary,
L. Pagano, S. Zimmerli,
G. Petrikkos.



Brd European Conference on Infections in Leukemia

Background

- Zygomycosis is the third most common invasive fungal infection after candidiasis and aspergillosis.
- It has a high mortality, even when appropriately treated.
- There are no guidelines for the treatment of zygomycosis.



Questions

- What is the optimal
 - First line antifungal therapy for zygomycosis?
 - Second line antifungal therapy for zygomycosis?
 - Dosing and duration of antifungal therapy?
- What is the role of surgery in the treatment of zygomycosis?
- What are the indications for combination therapy or adjunctive treatments?



Methods

- Literature review
 - Pubmed
 - ICAAC, ECCMID, ASH, ASCO and EBMT
- IDSA grading system



3rd European Conference on Infections in Leukemia

IDSA-United States Public Health Service grading system for ranking recommendations

Quality of evidence	Strength of recommendation
Evidence from <u>></u> 1 properly randomized, controlled trial	A Good evidence to support a recommendation for use
II Evidence from ≥ well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from >1 center); from multiple time-series; or from dramatic results from uncontrolled experiments	B Moderate evidence to support a recommendation for use
III Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees	C Poor evidence to support a recommendation

Proportion of hematological malignancies in zygomycoses caseseries

	Years	Population	Cases	%
Roden et al, Clin Infect Dis	1887-2003	929 cases	154 HM	17
2005; 41:634-53			44 HSCT	5
Zaoutis et al, Ped Infect Dis J, 2007; 26:723-27	1939-2007	157 pediatrics	28 HM 9 HSCT	14 4
Skiada et al, CMI) (ECMM)	2005-2007	230 cases	123 HM	53
Ruping et al, ICAAC 2009 (M-1049) (Fungiscope)	2006-2009	41 cases	26	63.4



Incidence of zygomycoses in HMs treated with conventional approaches

	Years	Population	Cases	%
Pagano et al, Br J Haematol 1997;99: 331-6 (GIMEMA)	1987-1995	3148 acute leukemia	37	1
Nosari et al, Haematologica 2000; 85:1068-71	1987-1999	653 acute Ieukemia	13	1.6
Kontoyiannis et al, CID 2000; 30:851-6	1989-1998	624 autopsy in HMs	12	1.9
Kontoyiannis et al, CID 2000; 30:851-6	1989–1993 1994–1998	8 per 100,000 20 per 100,000		
Pagano et al, Haematologica 2006; 91:1068 <mark>(SEIFEM)</mark>	1999-2003	11802 HM	14	0.1



Incidence of zygomycoses in HSCTs

	Years	Population	Cases
Marr at al, CID 2002: 100:4358-66	1985-1999	5589 HSCT	29
Park et al, IDSA 2005 (TRANSNET)	2001-2004	9314 HSCT	37
Pagano et al, Clin Infect Dis 2007; 45:1161 <mark>(SEIFEM)</mark>	1999-2003	1249 alloHSCT 1979 autoHSCT	1
Garcia Vidal et al, Clin Infect Dis 2008; 47:1041–50	1998-2002	1248 HSCT	8
Neofytos et al., Clin Infect Dis 2009; 48:265–73 (PATH-Alliance)	2004-2007	alloHSCT autoHSCT	12 8



Role of amphotericin B in the treatment of zygomycosis



3rd European Conference on Infections in Leukemia

Amphotericin B - Activity *in vitro* *

	AMB	PCZ	ITC
	% ≤1ug/mL	% ≤0.5µg/mL	% ≤0.5µg/mL
Rhizopus sp (101)	100	80	62
Rhizopus arrhizus (20)	100	64	50
Rhizopus microsporus (12)	100	78	60
Mucor sp. (41)	94	70	57
Mucor circinelloides (6)	100	0	0
Rhizomucor sp.(5)	100	67	67
Absidia corymbifera (9)	100	100	100
Cunninghamella sp. (13)	63	75	29
Apophysomyces elegans (6)	100	83	80



3rd European Conference on Infections in Leukemia

Almyroudis et al., AAC 07

* M38-A

Amphotericin B - in vitro data

- For the *Mucorales* as a whole, amphotericin B was the most active antifungal agent, with the majority of strains displaying MICs near the suggested breakpoint of 1 g/ml.
- Only some strains of *Cunninghamella* sp. had higher MICs.



Brd European Conference on Infections in Leukemia

Almyroudis et al., AAC 07

Amphotericin B - Activity in vitro

- 37 strains / 7 species of zygomycetes
- NCCLS M38-P; 48h; 80% inhibition (azoles) / 100% (Amb)

Organism (no. of isolates)	MIC (µg/ml)				
and agent	Mean	Range	50%ª	90%ª	
POS	1.22	0.015-8	0.25	4	
ITC	1.95	0.015 - 8	0.5	8	
VRC	41.14	0.5 -> 64	>64	>64	
FLC	57.82	1->64	>64	>64	
AMB	0.33	0.03-2	0.25	0.5	

" MIC at which 50% or 90% of the isolates were inhibited.



Amphotericin B - Activity in vitro

Table 4. Susceptibilities of zygomycetes to various antifungal agents*

Organism	Antifungal	MIC ₉₀ (mcg/mL)	Percent inhibited at MIC ≤1 mcg/mL
	Posaconazole	1-4	40
	Voriconazole	1-8+	40
Rhizopus species	Itraconazole	1-8+	20
	Amphotericin B	0.5–1	100
	Caspofungin	>8	0
	Posaconazole	0.5–8+	67
	Voriconazole	1-8+	33
Mucor species	Itraconazole	2-8+	0
	Amphotericin B	0.5–1	100
	Caspofungin	>8	0



3rd European Conference on Infections in Leukemia Proc (Bayl Univ Med Cent) 2007;20:188–196

Amphotericin B- Efficacy in vivo


ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2008, p. 1573–1576 0066-4804/08/\$08.00+0 doi:10.1128/AAC.01488-07 Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Comparison of Lipid Amphotericin B Preparations in Treating Murine Zygomycosis[∀]

Ashraf S. Ibrahim,^{1,2}* Teclegiorgis Gebremariam,¹ Mohamed I. Husseiny,¹ David A. Stevens,^{3,4} Yue Fu,^{1,2} John E. Edwards, Jr.,^{1,2} and Brad Spellberg^{1,2}

Efficacy of LAmB and ABLC in the neutropenic mouse model of zygomycosis.

"There was no significant difference in survival among the mice treated with the different antifungals at the different doses, although, again, the highest number of surviving mice was in the group treated with LAmB at 15 mg/kg/day."





Vol. 52, 1

Clinical efficacy of Ampho-B

 Amphotericin B deoxycholate has been the "gold standard" for more than 40 years

No randomized trials

Only case-series available



Roden et al. CID 2005; 41:634–53

- In an overview of 929 case reports of zygomycosis, among 532 cases treated with AmB, the response rate was 61%, compared to 69% of the 116 patients treated with lipid compounds of AmB.
- Both haematological and nonhaematological patients were included in this review



Improved Outcome of Zygomycosis in Patients with Hematological Diseases?

B. GLEISSNER^{a,*}, A. SCHILLING^b, I. ANAGNOSTOPOLOUS^c, I. SIEHL^a and E. THIEL^a

Leukemia & Lymphoma, July 2004 Vol. 45 (7), pp. 1351-1360

- Review of 120 cases from 1986 to 2002 with hematological malignancy and zygomycosis.
- 73 patients received d-AmB
- 26 patients received L-AMB
- 5 patients received ABLC
- 2 patients received ABCD
- **Survival: 39%** with d-AmB, **62%** with L-AmB and **75%** with d-AmB and sequential L-AmB.



Liposomal Amphotericin B

Study	No of cases	Antifungal median daily dose	Underlying disease	Survival (%)
Walsh et al (2001)	5	7.5-15 mg/kg	Not reported	
Pagano et al (2004)	12	3 mg/kg	HM	19/28
Cordonnier et al (2007)	6	4 mg/kg	HM (including allo-HSCT)	(68%)
Cornely et al (2007)	3	3 mg/kg	HM	



Amphotericin B lipid complex

Study	No of cases	Antifungal median daily dose	Underlying disease	Survival (%)
Walsh <i>et al</i> (1998)	24	5 mg/kg	4 HM 2 allo-HSCT	63/88
Larkin and Montero (2003)	64	4.82 mg/kg	17 HM 8 allo-HSCT	(71%)



3rd European Conference on Infections in Leukemia

Amphotericin B colloidal dispersion

Study	No of cases	Antifungal median daily dose	Underlying disease	Survival (%)
Oppenheim <i>et al</i> (1995)	4	6 mg/kg	HM	16/24
Herbrecht <i>et al</i> (2001)	20	4.8 ± 1.8 mg/kg	5 HM 7 allo- HSCT	(67%)



3rd European Conference on Infections in Leukemia

Role of posaconazole in the treatment of zygomycosis



3rd European Conference on Infections in Leukemia

Posaconazole- Activity in vitro

- 37 strains / 7 species of zygomycetes
- NCCLS M38-P; 48h; 80% inhibition (azoles) / 100% (Amb)

	MIC50 [µg/mL]	MIC90 [µg/mL]
POS	0.25	4
ITC	0.5	8
VRC	>64	>64
FLC	>64	>64
AMB	0.25	0.5



3rd European Conference on Infections in Leukemia

Posaconazole- Activity in vitro

37 strains / 7 species of zygomycetes

• NCCLS M38-P; 48h; 80% inhibition (azoles) / 100% (Amb)

Organism (no. of isolates)	MIC (µg/ml)				
and agent	Mean	Range	50%ª	90%ª	
POS	1.22	0.015-8	0.25	4	
ITC	1.95	0.015 - 8	0.5	8	
VRC	41.14	0.5->64	>64	>64	
FLC	57.82	1->64	>64	>64	
AMB	0.33	0.03-2	0.25	0.5	

" MIC at which 50% or 90% of the isolates were inhibited.



Posaconazole- Activity in vitro

In vitro activity against 45 zygomycetes isolates of 6 species obtained by the CLSI M38-A procedure at 48 h

	MIC ₅₀	MIC ₉₀	MEC ^a	MIC range
AMB ITC VC POS CAS	$1 \\ 4 \\ > 16 \\ 0.5 \\ > 256$	4 > 16 > 16 2 > 256	256	0.125 > 16 0.5 > 16 8 - > 16 0.25 - > 16 128 - > 256



3rd European Conference on Infections in Leukemia

Torres et al., AAC 06

Posaconazole: Summary, Activity *in vitro*

- Zygomycetes are a heterogenous group of fungi with variable, but overall favorable susceptibility in vitro to posaconazole 1
- Posaconazole fungicidal against *Rhizopus* and *Mucor* spp with <70% killing at 6 and 99.9% at 48h²
- No antagonism between posaconazole and AMB against zygomycetes in vitro ³

¹ Sun AAC 02; Gil-Lamaignere JAC 05; Torres AAC 06; Antachopoulos JCM 06; AlmyroudisAAC 07; ² Krishnan DMID 09; ³Arikan Med Mycol 08; Perkhofer AAC 08



3rd European Conference on Infections in Leukemia

Posaconazole- Efficacy in vivo

- Lethal non-immunocompromised mouse model of diss. mucormycosis
- AmB 1, ITC 50 BID, POS 5, 25, 40 (100) QD

. D mierosporus	Isolate	MIC (µg/ml)			
• R. microsporus		Amphotencin B	lt raconazole	Posaconazole	
 R. oryzae 	R. microsporus AZN 1185	0.25	>16	1	
• A. corymbifera	R. oryzae AZN 6373 A. corymbifera AZN 4895	$\frac{1}{0.06}$	0.5 0.03	$0.25 \\ 0.12$	

"MICs of amphoterin B and itraconazole against R microsporus and A. corymbifera are from reference 3.



3rd European Conference on Infections in Leukemia

Dannaoui et al., AAC 03

Posaconazole: Summary, Efficacy *in vivo*

- Zygomycetes are a heterogenous group of fungi with variable virulence and variable host responses ¹
- Posaconazole prolonged was effective for disseminated Mucor spp. and R.microsporus in neutropenic mice, had no effects against R. oryzae, and partial benefit against A. corymbifera in non-immunocompromised mice ²
- No consistent in vitro-in vivo correlation against *R.oryzae, A.corymbifera,* and *R.microsporus* ³
- Combination of POS and L-AMB / DAMB no better than L-AMB or DAMB against *R.oryzae* in ketoacidotic or neutropenic mice ⁴

¹ Petraitiene ICAAC 08; ² Sun AAC 02; Dannaoui AAC 03; Ibrahim AAC 09; ³ Dannaoui AAC 03; Rodriguez AAC submitted ; ⁴ Rodriguez AAC 08; Ibrahim AAC 09;



3rd European Conference on Infections in Leukemia

Posaconazole vs. Zygomycosis

- Ergosterol biosynthesis valid target
- however
 - Zygomycetes are heterogeneous in terms of susceptibility
 - Challenge of in vitro / in vivo correlation
- Posaconazole effective in patients ?



Posaconazole Clinical – *Greenberg et al. (2006)*

- 24 patients receiving POS on protocols for pts. with refractory infections or intolerance to standard therapies
- Proven rhinocerebral (11); single site (9); and disseminated infections (4)
- allo-BMT/HM,15; other: 9
- Pretreatment with AMBs: 22/24; surgery: 18/24
- Dosage: 800 mg/d for median of 182 d (8-1004)

Overall successful outcome (I.D.): 19/24 (79 %) Estimated survival at day +90: 78 %

 Survival associated with surgery, stabilization of underlying condition, and absence of dissemination



Posaconazole Clinical – Van Burik et al. (2006)

- Retrospective analysis of SPRI compassionate use protocol including 91 pts. with proven (69)/probable (22) zygomycosis refractory (81) or intolerant (10) to prior antifungal therapy
 - 62% single site, 38% > one site
 - 53% HM, 33% IDDM
 - >85% pretreatment with LFABs, 70% surgical resection
- 800 mg in divided dosages for 6-1005 days

CR/PR at 12 weeks (ITT): 55/91 (60%) - 14 % CR, 46% PR, 21% stable disease



3rª European Conference « Infections » Leukemia

v. Burik et al. CID 06

Posaconazole Clinical: Chamilos et al. (2008)

Outcome among 70 consecutive patients with hematologic malignancy who had zygomycosis at MDACC during 1989–2006:

	Outcome®		Univariate analysis		Multivariate analysis	
Characteristic	Death $(n = 46)$	Survival $(n = 24)$	OR (95% CI)	Р	OR (95% CI)	Ρ
Treatment						
Delayed treatment (≽6 days after diagnosis)	29 (63)	6 (25)	8.6 (1.7-43.4)	.009	8.1 (1.7-38.2)	.008
AMB-deoxycholate ^h	8 (17)	4 (17)		.8		
Lipid AMB	14 (30)	6 (25)		.7		
Liposomal AMB	24 (52)	14 (58)		.8		
Duration of treatment, median days (range)	12 (1-96)	35 (1-133)		<.001		
≥7 days of AMB-based treatment	29 (63)	24 (100)	0.03 (0.001-0.6)	<.001		
AMB-based treatment plus caspofungin	11 (24)	10 (42)		.1		
Salvage posaconazole treatment ⁱ	5 (11)	10 (42)	0.1 (0.04–0.7)	.005	0.1 (0.01-0.66)	.01
WBC transfusions	12 (26)	3 (13)		.2		
GM-CSF or G-CSF	37 (80)	14 (58)		.08		
IFN-γ	4 (9)	2 (8)		.6		
Surgery ^k	13 (28)	9 (38)		.4		



3rd European Conference on Infections in Leukemia

Role of surgical treatment

Rationale: to reduce fungal mass; to debride necrotic tissue

- Surgery may be of benefit in localized zygomycosis, particularly cutaneous-soft tissue and rhino-orbitalcerebral disease, fewer data on pulmonary disease
- Benefit of surgery diminishes in disseminated disease



Other antifungal agents beside amphotericin B and posaconazole

Flucytosine, fluconazole, voriconazole and terbinafine have no meaningful activity

Itraconazole

- Some variable in vitro and experimental activity, best activity being reported against Absidia spp. (Dannaoui et al, 2002)
- Rare case reports (Eisen et al, 2004; Liao et al., 1995; Parthiban et al., 1998; Zhao et al., 2009), insufficient to support its use in zygomycosis

Isavuconazole

- Broad spectrum triazole including Mucorales with MIC50 values of 1 to 4 mg/mL and MIC90 values of 4 to 16 mg/mL (Verweij et al., 2009)
 So far no clinical data
- So far no clinical data

Caspofungin, anidulafungin and micafungin

- No efficacy in vitro against Zygomycetes (Almyroudis et al., 2007; Espinel-Ingroff et al., 1998; Isham et al., 2006)
- Caspofungin has shown efficacy in an animal model but with an inverse-dose response relationship: low dose more effective high dose (Ibrahim et al., 2005)
- No clinical data are available with echinocandin in monotherapy

No recommendation for the use of any of these agents as monotherapy



Combination therapy: experimental data

- Amphotericin B lipid complex combined to caspofungin (Spellberg et al., 2005)
 - Improved survival of diabetic ketoacidotic mice infected with *Rhizopus* oryzae
- Liposomal amphotericin combined to anidulafungin or micafungin (lbrahim et al, 2008)
 - Improved survival in mice infected intravenously with *Rhizopus oryzae* compared to placebo or monotherapy arms
 - Paradoxical effect (low dose more active than high dose) with micafungin but not with anidulafungin
- Liposomal amphotericin B combined to posaconazole (Ibrahim et al., 2009)
 - In mice infected with Rhizopus oryzae
 - Combination did not improve survival compared to liposomal amphotericin B alone



Combination therapy: clinical data

- Retrospective study in rhino-orbito-cerebral zygomycosis (Reed et al., 2008)
 - Monotherapy with AmB formulation (31 patients) or a combination of caspofungin and ABLC or L-AmB (6 patients)
 - Patients receiving a combination had a higher response rate and survival
 - Limitations: rhinocerebral only, most pts had diabetes and all had surgery
- Combination of deferasirox and L-AmB (Spellberg et al, 2009)
 - 8 patients received deferasirox in addition to their antifungal therapy
 - Only events attributable to deferasirox were skin rashes in 2 patients.
 - -7 of the 8 patients responded to therapy.
 - Limitations: low number of pts, various combinations used in this study

• Combination of deferasirox and L-AmB (Spellberg et al, 2012)

 A double-blinded, randomized, placebo-controlled phase II clinical trial of the safety and exploratory efficacy of adjunctive deferasirox therapy for patients with mucormycosis treated with L-AmB (the deferasirox-AmBisome therapy for mucormycosis [DEFEAT Mucor] study) failed to demonstrate a benefit of



combination therapy

3rd European Conference on Infections in Leukemia

Adjunctive treatments (deferasirox)

Rationale: Chelation of iron (by chelators that are not siderophores for zygomycetes) decreases availability of this factor essential for growth and pathogenicity of zygomycetes

- Chelation of iron may be beneficial.
 - The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study failed to demonstrate a benefit.
- Further studies are needed in order to clarify the potential of deferasirox to add benefit to lipid polyene therapy for mucormycosis
- Current data do not support establish conclusively that deferasirox or deferiprone should be used in the treatment of mucormycosis.



Adjunctive treatments

Hyperbaric oxygen

Rationale: *in vitro* suppressive effect on growth of zygomycetes. Reduction of tissue hypoxia and acidosis: enhanced killing of zygomycetes by neutrophils, reduced availability of free iron, enhanced oxydative action of amphotericin B.

 Hyperbaric oxygen may be beneficial, particularly in diabetic patients



Recommendation for first line (part 1)

Management includes antifungal therapy, control of underlying conditions and surgery. A II

Antifungal therapy

- AmB deoxycholateC IILinesemel AmBD II 1
- Liposomal AmBB II 1ABLCB II 1
- ABCD
- Posaconazole
- **Combination therapy**

C II CIII² CIII

¹ Liposomal amphotericin B should be preferred in CNS infection and/or renal failure.

² No data to support its use as first line treatment. May be used as an alternative when amphotericin B is <u>absolutely</u> contraindicated.



Recommendation for first line (part 2)

Management includes antifungal the underlying conditions and surgery.	rapy, control of A II
Control of underlying condition	A II ³
Surgery	
 rhino-orbito-cerebral 	AII
- soft tissue	AII
 localized pulmonary lesion 	BIII
- disseminated	CIII ⁴
Hyperbaric oxygen	CIII

³ Control of underlying condition includes control of diabetes, hematopoietic growth factor if neutropenia, discontinuation/tapering of steroids, reduction of immunosuppressive therapy.

⁴ Surgery should be considered on a case by case basis, using a multidisciplinary approach.



Recommendation for second line and maintenance therapy

Second line

Management includes antifungal therapy, control of underlying disease and surgery.

Posaconazole	BII
Combination lipid AmB and caspofungin	BII
Combination lipid AmB and posaconazole	CIII
Combination with deferasirox	CIII

Maintenance therapy

Posaconazole	B III ⁵

⁵ Overlap of a few days (at least 5) with first line therapy to obtain appropriate serum levels. Monitoring of serum levels might be indicated

